<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9405014
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     01
    </month>
    <day>
     22
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     01
    </month>
    <day>
     22
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0392-9590
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       16
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        1997
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      International angiology : a journal of the International Union of Angiology
     </title>
     <isoabbreviation>
      Int Angiol
     </isoabbreviation>
    </journal>
    <articletitle>
     The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin.
    </articletitle>
    <pagination>
     <medlinepgn>
      189-92
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To elucidate the risk of pulmonary embolism (PE) in patients with deep vein thrombosis (DVT) who are kept walking with compression bandages.
     </abstracttext>
     <abstracttext label="EXPERIMENTAL DESIGN" nlmcategory="METHODS">
      Perfusion/ventilation scanning of the lungs was performed at admission and after 10 days of treatment.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      General community hospital.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      A total of 631 consecutive patients were studied (upper limit of the thrombi: iliofemoral vein, n=212; femoral or popliteal vein, n=302; lower leg, n=117). The patients received different dose regimens of low-molecular-weight heparin (dalteparin) subcutaneously.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The study revealed that the prevalence of PE at baseline was between 45.1% and 51% (95% CI 38.2-55.2 and 45.2-56.8% respectively) in patients with proximal DVT, and 31.9% (95% CI 23.6-41.2%) in those with DVT restricted to the lower leg. The majority of these cases of PE were completely asymptomatic. The incidence of a new PE, revealed by a second lung scan on day 10 after admission, was 7.0% (95% CI 3.9-11.4%) in patients with iliofemoral DVT, 5.5% (95% CI 3.2-8.7%) in those with femoropopliteal DVT and 2.7% (95% CI 0.6-7.6%) in those with lower-leg DVT. These incidence rates for new PEs were significantly lower than the rates previously reported (p&lt;0.01). The fatality rate was also lower compared with the literature: one patient suffered a fatal PE (0.2%; 95% CI 0-0.9%), four patients died from malignant tumours, and one from pneumonia. The frequency of malignant tumours was greater in this study than in the literature (23% in patients with iliofemoral DVT, 14% in those with femoropopliteal DVT and 9% in those with DVT of the lower leg).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Mobile patients with DVT do not need bed-rest. Low-molecular-weight heparin s.c., compression bandages and walking exercises make home-treatment of DVT feasible.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Dermatology, Wilhelminenspital, Vienna, Austria.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Partsch
      </lastname>
      <forename>
       H
      </forename>
      <initials>
       H
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kechavarz
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       KÃ¶hn
      </lastname>
      <forename>
       H
      </forename>
      <initials>
       H
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Mostbeck
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ITALY
    </country>
    <medlineta>
     Int Angiol
    </medlineta>
    <nlmuniqueid>
     8402693
    </nlmuniqueid>
    <issnlinking>
     0392-9590
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticoagulants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Heparin, Low-Molecular-Weight
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticoagulants
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bandages
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Femoral Vein
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heparin, Low-Molecular-Weight
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Iliac Vein
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Immobilization
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Incidence
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Leg
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood supply
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Popliteal Vein
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pulmonary Embolism
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Retrospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thromboembolism
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thrombophlebitis
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapy
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1997
     </year>
     <month>
      12
     </month>
     <day>
      24
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1997
     </year>
     <month>
      12
     </month>
     <day>
      24
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1997
     </year>
     <month>
      12
     </month>
     <day>
      24
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9405014
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

